Skip to main content
. 2012 Dec 12;11:416. doi: 10.1186/1475-2875-11-416

Table 2.

Baseline characteristics of patients at enrolment in the two groups

  Artesunate Mefloquine (n = 157) Artemether Lumefantrine (n = 153) p value
Age (mean ± SD, years)
25 ± 11
23.2 ± 10,5
0.15
Weight (mean ± SD, Kg)
62.1 ± 11.8
58.2 ± 11.5
0.08
Sex ratio (male/female)
1.2
0.6
0.03
Temperature (mean ± SD)
37.8 ± 1.2
37.7 ± 1.1
0.41
Median Parasitemia (trophozoites/μL)
17411
17688
0.88
Mean haemoglobin (g/dl)
12.2 ± 1.7
11.7 ± 1.7
0.99
Anaemia (Hb < 11 g/dl,%)
36.3
40.5
0.44
ASAT (UI/L, mean ± SD)
31.2 ± 18.7
33.1 ± 16.8
0.38
Patients with normal level of ASAT (ASAT < 40 UI/L) (%)
128 (81.5%)
123 (80.4%)
0.79
ALAT (UI/L, mean ± SD)
28.2 ± 20.3
26.3 ± 24.1
0.47
Patients with normal level of ALAT (ALAT < 40 UI/L) (%)
119 (82.1%)
138 (90.2%)
0.04
Creatinine (mean ± SD)
7.6 ± 5.4
8.2 ± 3.5
0.24
Patients with normal level of creatinine (<13 mg/L) (%)
148 (94.3%)
143 (93.5%)
0.76
Median Bilirubunemia (mg/L)
1.91
1.71
0.51
Patients with normal level of Biliribunemia (<10 mg/L) (%) 48 (30.6%) 55 (35.9%) 0.31